Lux raises $36M, licenses ISA247
Lux Biosciences has raised $36 million in its first round and inked a licensing deal for a Phase III drug from Isotechnika. HBM Partners, Novo A/S and SV Life Sciences participated in the round for Lux Biosciences, which is concentrating on ophthalmic therapies. To that end, it licensed Isotechnika's Phase III candidate ISA247, a calcineurin inhibitor which is being developed for uveitis, an inflammatory eye disease. Lux believes the drug has other applications as well. Lux plans to begin a pivotal trial in 2007.
- read this release on Lux's first round
Comments